Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyrrolidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL28886795 | 1.00 | ALDH1A1 (0.80) | — | |
| Pyrrolidine SCHEMBL18585434 | 1.00 | — | — | |
| Pyrrolidine SCHEMBL3658215 | 1.00 | — | — | |
| Pyrrolidine SCHEMBL28886799 | 1.00 | ALDH1A1 (0.80) | — | |
| Hydrochloric Acid SCHEMBL7475923 | 0.95 | ALDH1A1 (0.90) | — | |
| Piperidine SCHEMBL16431798 | 0.95 | ALDH1A1 (0.90) | — | |
| Pyrrolidine SCHEMBL10910489 | 0.95 | — | — | |
| Piperidine SCHEMBL163097 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL20504414 | 0.95 | ALDH1A1 (0.90) | — | |
| Hydrochloric Acid SCHEMBL11805890 | 0.95 | ALDH1A1 (0.90) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 929 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459896-B2 | Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile | AMGEN INC. (US) | 2025-11-04 | — | — | US | claimed |
| US-20250206705-A1 | PROCESS FOR PREPARING 4-METHYL-2-PROPAN-2-YL-PYRIDINE-3-CARBONITRILE | AMGEN INC. (US) | 2025-06-26 | — | — | US | claimed |
| US-20250188036-A1 | A PROCESS FOR PREPARING 4-METHYL-2-PROPAN-2-YL-PYRIDINE-3-CARBONITRILE | AMGEN INC. (US) | 2025-06-12 | — | — | US | claimed |
| CN-120004697-A | Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material | 同济大学 | 2025-05-16 | — | — | CN | claimed |
| CN-118829629-A | Process for the preparation of 4-methyl-2-prop-2-yl-pyridine-3-carbonitrile | 美国安进公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118475207-A | Perovskite solar cell, preparation method thereof and laminated cell | 北京曜能科技有限公司 | 2024-08-09 | — | — | CN | claimed |
| CN-113543706-B | Electrode comprising a conductive acrylate-based pressure sensitive adhesive | 汉高股份有限及两合公司 | 2024-07-23 | — | — | CN | claimed |
| CN-118235027-A | Ion conductive composition for thermal sensor | 汉高股份有限及两合公司 | 2024-06-21 | — | — | CN | claimed |
| WO-2023172858-A9 | A PROCESS FOR PREPARING 4-METHYL-2-PROPAN-2-YL-PYRIDINE-3-CARBONITRILE | AMGEN INC. (US) | 2024-05-16 | — | — | WO | claimed |
| CN-117727853-A | Negative electrode composite carrier with protective layer and preparation method thereof | 超威电源集团有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-101229373-A | Medicine compounds for treating diabetic nephropathy | LUNAN PHARM GROUP CORP (CN) | 2008-07-30 | — | — | CN | claimed |
| US-7300797-B2 | Lysis reagent for blood cell analysis | IMMUNOTECH, S.A. (FR) | 2007-11-27 | — | — | US | claimed |
| EP-1695970-A1 | Peptides useful for competitive modulation of dipeptidyl peptidase IV catalysis | Prosidion Limited (GB) | 2006-08-30 | — | — | EP | claimed |
| EP-0955543-B1 | New reagents and methods for erythrocyte lysis | IMMUNOTECH SA (FR) | 2003-04-16 | — | — | EP | claimed |
| US-6143567-A | Reagents and a method for the lysis of erythrocytes | IMMUNOTECH (FR) | 2000-11-07 | — | — | US | claimed |
| EP-0770386-B1 | Lanperisone formulation | NIPPON KAYAKU KK (JP) | 2000-02-02 | — | — | EP | claimed |
| US-5843478-A | Lanperisone formulation | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1998-12-01 | — | — | US | claimed |
| CN-1162447-A | Preparation for central nerves of muscle | NIPPON KAYAKU KK (JP) | 1997-10-22 | — | — | CN | claimed |
| EP-0770386-A1 | Lanperisone formulation | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1997-05-02 | — | — | EP | claimed |
| WO-1990010021-A1 | SOLUBILIZATION OF INDOMETHACIN AND PIROXICAM BY A QUATERNIZED POLYMER | GAF CHEMICALS CORPORATION (US) | 1990-09-07 | — | — | WO | claimed |